These results collectively support that immunosuppression by the ADT‐induced aggregation of MDSCs drives PCa progression and points to IL‐1β as an important immune therapy target for advanced PCa in combination with ADT (Figure7). The gene discussed is IL1B; the disease is posterior cortical atrophy.